Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Royalty Pharma plc shares valued at $2,773,956 were sold by Coyne Terrance P. on Dec 01 ’25. At $39.87 per share, Coyne Terrance P. sold 69,582 shares. The insider’s holdings dropped to 47,260 shares worth approximately $1.85 million following the completion of this transaction.
Also, Urist Marshall sold 23,333 shares, netting a total of over 931,633 in proceeds. Following the sale of shares at $39.93 each, the insider now holds 183,334 shares.
Before that, Urist Marshall had sold 18,242 shares from its account. In a trade valued at $727,856, the EVP, Research & Investments traded Royalty Pharma plc shares for $39.90 each. Upon closing the transaction, the insider’s holdings decreased to 18,242 shares, worth approximately $1.0 million.
As published in their initiating research note from Goldman on September 30, 2025, Royalty Pharma plc [RPRX] has been a Buy and the price target has been revised to $42. Analysts at Morgan Stanley started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid May. As of June 03, 2024, UBS has decreased its “Buy” rating to a “Neutral” for RPRX.
Analyzing RPRX Stock Performance
On last trading session, Royalty Pharma plc [NASDAQ: RPRX] plunged -1.14% to $39.15. The stock’s lowest price that day was $38.98, but it reached a high of $39.64 in the same session. During the last five days, there has been a drop of approximately -1.73%. Over the course of the year, Royalty Pharma plc shares have jumped approximately 48.13%. Shares of the company reached a 52-week high of $41.24 on 11/06/25 and a 52-week low of $25.40 on 01/06/25.
Support And Resistance Levels for Royalty Pharma plc (RPRX)
According to the 24-hour chart, there is a support level at 38.87, which, if violated, would cause prices to drop to 38.60. In the upper region, resistance lies at 39.53. The next price resistance is at 39.92. RSI (Relative Strength Index) is 52.72 on the 14-day chart, showing neutral technical sentiment.
Is Royalty Pharma plc subject to short interest?
Stocks of Royalty Pharma plc saw a sharp rise in short interest on 2025-11-14 jumping by 10.45 million shares to 24.03 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 13.58 million shares. A jump of 43.5% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.62 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.62.
Which companies own the most shares of Royalty Pharma plc (RPRX)?
In terms of Royalty Pharma plc share price expectations, FactSet research, analysts set an average price target of 48 in the next 12 months, up nearly 21.21% from the previous closing price of $39.6. Analysts anticipate Royalty Pharma plc stock to reach 54 by 2025, with the lowest price target being 42. In spite of this, 6 analysts ranked Royalty Pharma plc stock as Buy at the end of 2025. On May 13, 2022, Scotiabank assigned a price target of “a Sector outperform” to the stock and initiated coverage with a $53.
